• Mi Young Lee, Dong Seop Choi, Moon Kyu Lee, Hyoung Woo Lee, Tae Sun Park, Doo Man Kim, Choon Hee Chung, Duk Kyu Kim, In Joo Kim, Hak Chul Jang, Yong Soo Park, Hyuk Sang Kwon, Seung Hun Lee, and Hee Kang Shin.
• Division of Endocrinology & Metabolism, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
• J. Korean Med. Sci. 2014 Jan 1; 29 (1): 909790-7.

AbstractWe studied the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetes patients whose blood glucose levels were inadequately controlled with basal insulin alone or in combination with metformin (or a sulfonylurea). This study was a 24-week prospective, open-label, randomized, active-controlled multi-center study. Participants were randomized to receive either acarbose (n=59, 300 mg/day) or voglibose (n=62, 0.9 mg/day). The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose (from 8.43% ± 0.71% to 7.71% ± 0.93%) and voglibose groups (from 8.38% ± 0.73% to 7.68% ± 0.94%). The mean fasting plasma glucose level and self-monitoring of blood glucose data from 1 hr before and after each meal were significantly decreased at week 24 in comparison to baseline in both groups. The levels 1 hr after dinner at week 24 were significantly decreased in the acarbose group (from 233.54 ± 69.38 to 176.80 ± 46.63 mg/dL) compared with the voglibose group (from 224.18 ± 70.07 to 193.01 ± 55.39 mg/dL). In conclusion, both acarbose and voglibose are efficacious and safe in patients with type 2 diabetes who are inadequately controlled with basal insulin. (ClinicalTrials.gov number, NCT00970528).

33 keywords...

hide…